Role of FoxP3 + Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy
Human Gene Therapy · 2024-07 · 35 (13-14) · 439-450
DOI: 10.1089/hum.2023.227 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Human Gene Therapy, online erschienen am 17.07.2024. Verfasst von Maite Muñoz-Melero und 1 weiteren Autor:innen. Beteiligte Einrichtung: Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, Indiana, USA. Hauptthemen laut MEDLINE: Dependovirus, T-Lymphocytes, Regulatory, Genetic Therapy, Forkhead Transcription Factors. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 129 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS.
Abstract (Originalsprache)
Adeno-associated virus (AAV) gene therapy is making rapid strides owing to its wide range of therapeutic applications. However, development of serious immune responses to the capsid antigen or the therapeutic transgene product hinders its full clinical impact. Immune suppressive (IS) drug treatments have been used in various clinical trials to prevent the deleterious effects of cytotoxic T cells to the viral vector or transgene, although there is no consensus on the best treatment regimen, dosage, or schedule. Regulatory T cells (Tregs) are crucial for maintaining tolerance against self or nonself antigens. Of importance, Tregs also play an important role in dampening immune responses to AAV gene therapy, including tolerance induction to the transgene product. Approaches to harness the tolerogenic effect of Tregs include the use of selective IS drugs that expand existing Tregs, and skew activated conventional T cells into antigen-specific peripherally induced Tregs. In addition, Tregs can be expanded ex vivo and delivered as cellular therapy. Furthermore, receptor engineering can be used to increase the potency and specificity of Tregs allowing for suppression at lower doses and reducing the risk of disrupting protective immunity. Because immune-mediated toxicities to AAV vectors are a concern in the clinic, strategies that can enhance or preserve Treg function should be considered to improve both the safety and efficacy of AAV gene therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Herman B Wells Center for Pediatric Research, Indiana University, Indianapolis, Indiana, USA.
ORCID-Profile: Moanaro Biswas
Förderung
- NHLBI NIH HHS
Zitieren
APA
Muñoz-Melero, M., & Biswas, M. (2024). Role of FoxP3 + Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy. Human Gene Therapy, 35(13-14), 439-450. https://doi.org/10.1089/hum.2023.227
Vancouver
Muñoz-Melero M, Biswas M. Role of FoxP3 + Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy. Human Gene Therapy. 2024;35(13-14):439-450. doi:10.1089/hum.2023.227
BibTeX
@article{MuozMelero2024,
author = {Muñoz-Melero, Maite and Biswas, Moanaro},
title = {Role of FoxP3 + Regulatory T Cells in Modulating Immune Responses to Adeno-Associated Virus Gene Therapy},
journal = {Human Gene Therapy},
year = {2024},
volume = {35},
number = {13-14},
pages = {439--450},
doi = {10.1089/hum.2023.227}
}
EUVIMED